Neonatal Neuroblastoma: the Controversy of Treatment, Clinical Features and Outcome

ZHOU Yao-dong,LI Kai,ZHENG Shan,CHEN Lian
DOI: https://doi.org/10.3760/cma.j.issn.0253-3006.2011.09.001
2011-01-01
Abstract:Objective To review the clinical features and outcome of newborns with neuroblastoma. Methods A medical record review and retrospective data analysis were performed on the neonatal neuroblastoma between January 2001 and December 2009, including clinical features, stages, bionomics, treatment and outcome. Results There were 14 patients with 8 males and 6 females. There were 5 cases in stageⅠ, 1 in stage Ⅱ , 1 in stage Ⅲ, 1 in stage Ⅳand 6 in stage Ⅳs, respectively.Tumor site distribution were retroperitoneum in 8 cases (6 was in adrenal gland site of the 8), thoracic cavity in 8 and pelvis in 2. N-myc amplification was detected in 3 out of 12 available cases. According to the Shimada pathology classification, the ratio of unfavorable histology (UH) to favorable histology (FH) was 4 to 8. Eight patients received surgical excision, in which 6 were completely resected. The 2-year overall survival (OS) of neonatal neuroblastoma patients was 92. 9%. Two-year OS of the simple chemotherapy group was not as higher as that of no chemotherapy group. Two-year OS of N-myc amplification group was lower than that of no amplification group(P = 0. 021 ). One patient died of complication of chemotherapy. ConclusionsThe prognosis of NB in neonates is fairly good except the patients with N-myc amplification or elevated vanillymandelic(VMA). There was no difference in the the five years of OS rate between simple chemotherapy and simple operation. Newborns with neuroblastoma were more sensitive and vulnerable to chemotherapy, operation and other therapeutic modalities.
What problem does this paper attempt to address?